Physician profile
Suresh Kunapareddy
NPI 1285742296
$29,587.53
in general payments reported to CMS, 2019-2025
77 companies · $3,643 in 2025
The $3,643 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,905 · 2020: $1,713 · 2021: $5,712 · 2022: $4,552 · 2023: $5,353 · 2024: $3,710 · 2025: $3,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $539 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,067.06 |
| Education | $538.79 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,858.83 | 2019-2025 | Tecvayli, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $2,304.33 | 2019-2025 | Imfinzi, Datroway, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,793.85 | 2019-2025 | Piqray, Kisqali |
| E.R. Squibb & Sons, L.L.C. | $1,529.79 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $1,356.53 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $1,276.00 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Pfizer INC. | $1,258.31 | 2019-2025 | |
| Genzyme Corporation | $1,189.27 | 2019-2025 | |
| Genentech USA, INC. | $1,065.87 | 2019-2025 | Tecentriq, Phesgo, Lunsumio |
| Lilly USA, LLC | $993.93 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Abbvie INC. | $983.88 | 2019-2025 | |
| Incyte Corporation | $880.73 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $826.68 | 2020-2024 | Xtandi |
| Celgene Corporation | $808.17 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Daiichi Sankyo INC. | $806.56 | 2019-2025 | Enhertu, Injectafer, Datroway |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Kunapareddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.